Application of Terminalia chebula and active monomers thereof in preparation of products against omicron virus

Abstract

The present application belongs to the field of biotechnology, and specifically relates to the application of Terminalia chebula Retz and its active monomers in the preparation of products for inhibiting the novel coronavirus and resisting the Omicron virus. The present application found that the active monomers of Terminalia chebula Retz, i.e. Terminalia chebula tannin and punicalagin, have strong binding force and significant inhibitory effect on the main protease of SARS-CoV-2. It is also found for the first time that the active monomers of Terminalia chebula Retz, i.e. Terminalia chebula tannin and punicalagin, have significant inhibitory effect on Omicron BA.1 and BA.2 virus strains, and the half-effect concentration is extremely low. Therefore, Terminalia chebula Retz or its active monomers, i.e. Terminalia chebula tannin and punicalagin, or Terminalia chebula Retz extract containing at least one of the two active monomers, can be used to prepare products for inhibiting the novel coronavirus and resisting the Omicron virus.

Description

Technical Field

[0001] This invention belongs to the field of biotechnology, specifically relating to the application of Terminalia chebula and its active monomers in the preparation of products that inhibit the novel coronavirus and are effective against Omeprone virus. Background Technology

[0002] Omicron is a variant of the novel coronavirus with numerous mutations in its spike protein. Some of these mutations may be related to immune evasion potential and higher transmissibility. This not only causes the Omicron virus strain to infect and multiply in the bronchi at a much higher rate than the original novel coronavirus strain, making it more infectious, but also causes drugs that are effective against the novel coronavirus to be ineffective or less effective against the Omicron virus strain.

[0003] Furthermore, most of the currently disclosed drugs targeting the novel coronavirus are in the virtual target screening stage. However, experimental verification has revealed that the targets disclosed in existing literature for some drugs are not their actual effective targets, resulting in their inability to truly inhibit replication or kill the novel coronavirus. Mutant strains may not possess these truly effective targets, meaning these drugs may also be ineffective against variant strains of the novel coronavirus. Therefore, it is necessary to continue searching for drugs that are truly effective against the novel coronavirus and its variants. Summary of the Invention

[0004] To address the above problems, this invention provides the application of Terminalia chebula and its active monomers in the preparation of products that inhibit the novel coronavirus and are effective against Omeprone virus. Experimental studies have found that chebulic tannins and punicin in Terminalia chebula are effective against SARS-CoV-2. pro Both SARS-CoV-2 main protease and Omicron BA.1 and BA.2 viral strains showed significant inhibitory effects and can be used to prepare products that inhibit the novel coronavirus and are effective against Omicron virus.

[0005] To achieve the above-mentioned objectives, the embodiments of the present invention adopt the following technical solutions:

[0006] In a first aspect, the present invention provides the use of Terminalia chebula in the preparation of products that inhibit the novel coronavirus, wherein the active ingredient of the products that inhibit the novel coronavirus includes Terminalia chebula and / or Terminalia chebula extract, wherein the Terminalia chebula extract includes at least one of Terminalia chebulic tannic acid and punicin.

[0007] This invention demonstrates through experiments that the active monomers chebulic tannin and punicin in Terminalia chebula are effective against SARS-CoV-2M. pro It has a strong binding force and a significant inhibitory effect on it, thereby inhibiting the replication of the novel coronavirus.

[0008] The structural formula of Terminalia chebula tannic acid is shown in Formula I:

[0009]

[0010] The structural formula of punicalin is shown in Formula II:

[0011]

[0012]

[0013] In conjunction with the first aspect, the products include pharmaceuticals and daily chemical products.

[0014] Preferably, the daily chemical products include masks, mouthwash, hand sanitizer, alcohol-based sprays, alcohol-based gels, disinfectant solutions, and disinfectant wipes. By preparing the above-mentioned daily chemical products from Terminalia chebula and / or Terminalia chebula extracts containing at least one of Terminalia chebulic tannin and punicin, the replication of the novel coronavirus can be inhibited and the spread of the novel coronavirus reduced through respiratory protection, mouthwash, disinfection of exposed skin, environmental disinfection, and disinfection of items.

[0015] Preferably, the concentration of chebulic tannic acid in the mouthwash, hand sanitizer, alcohol-based spray, alcohol-based gel, disinfectant, and the liquid component soaking the disinfectant wipes is 0.039 μM to 160 μM. Experimental verification has shown that chebulic tannic acid at a concentration range of 0.039 μM to 160 μM is effective against SARS-CoV-2 M. pro It has a significant inhibitory effect.

[0016] Preferably, the concentration of punicalin in the mouthwash, hand sanitizer, alcohol-based spray, alcohol-based gel, disinfectant, and the liquid component soaking the disinfectant wipes is 0.195 μM to 30 μM. Experimental verification has shown that punicalin at a concentration range of 0.195 μM to 30 μM is effective against SARS-CoV-2 M. pro It has a significant inhibitory effect.

[0017] Other ingredients in the above-mentioned pharmaceuticals or daily chemical products may be selected according to the conventional ingredients of the corresponding products, preferably without adversely affecting the chemical properties and antiviral effects of chebulic tannic acid and punicalin; the preparation method may adopt the conventional method of the corresponding products, preferably without adversely affecting the chemical properties and stability of chebulic tannic acid and punicalin. This invention does not limit the specific ingredients or preparation methods of the above products.

[0018] Secondly, the present invention provides the use of Terminalia chebula in the preparation of products for treating Omeprón virus, wherein the active ingredients of the products include Terminalia chebula and / or Terminalia chebula extract, wherein the Terminalia chebula extract includes at least one of Terminalia chebulic tannic acid and punicin.

[0019] In vitro viral inhibition studies showed that the active monomers chebulic tannin and punicin from Terminalia chebula had significant inhibitory effects on Omicron BA.1 and BA.2 virus strains. Chebulic tannin also showed significant inhibitory effects on the EC50 of Omicron BA.1 virus. 50 The concentration was 0.81 μM for EC50 of Omicron BA.2. 50 The EC50 of punicalin against Omicron BA.1 was 1.19 μM. 50 The concentration was 4.37 μM, and the EC50 of OmicronBA.2 was... 50 The concentration was 3.65 μM, therefore, Terminalia chebula or Terminalia chebula extract containing at least one of these two active ingredients could be used as the active ingredient in anti-Omeprone virus products. However, there are currently no reports of Terminalia chebula or its active monomers chebulic tannin and punicin inhibiting Omeprone virus strains.

[0020] In conjunction with the second aspect, the strain of the Omeprone virus includes at least one of the BA.1 and BA.2 virus strains.

[0021] In conjunction with the second aspect, the products include pharmaceuticals and daily chemical products.

[0022] Preferably, the daily chemical products include masks, mouthwash, hand sanitizer, hand rinse spray, hand rinse gel, disinfectant, and disinfectant wipes.

[0023] Other ingredients in the above-mentioned pharmaceuticals or daily chemical products may be selected according to the conventional ingredients of the corresponding products, preferably without adversely affecting the chemical properties and antiviral effects of chebulic tannic acid and punicalin; the preparation method may adopt the conventional method of the corresponding products, preferably without adversely affecting the chemical properties and stability of chebulic tannic acid and punicalin. This invention does not limit the specific ingredients or preparation methods of the above products.

[0024] Thirdly, the present invention also provides the application of chebulic tannic acid in the preparation of products for treating Omeprone virus.

[0025] Other ingredients in the above products can be selected according to the conventional ingredients of the corresponding products, preferably without adversely affecting the chemical properties and antiviral effects of chebulic tannic acid; the preparation method can adopt the conventional method of the corresponding products, preferably without adversely affecting the chemical properties and stability of chebulic tannic acid. This invention does not limit the specific ingredients or preparation methods of the above products.

[0026] Fourthly, the present invention also provides the application of pungent glycoside in the preparation of products against Omeprone virus.

[0027] Other ingredients in the above-mentioned pharmaceuticals or daily chemical products may be selected according to the conventional ingredients of the corresponding products, preferably without adversely affecting the chemical properties and antiviral effects of pungent glycosides; the preparation method may adopt the conventional method of the corresponding products, preferably without adversely affecting the chemical properties and stability of pungent glycosides. This invention does not limit the specific ingredients or preparation methods of the above products.

[0028] The beneficial effects of this invention are: through in vitro enzyme inhibition activity assays and molecular interaction studies, this invention has for the first time discovered the active monomers of Terminalia chebula, chebulic tannin and punicin, against SARS-CoV-2 M. pro It exhibits strong binding affinity and can significantly inhibit its activity. Furthermore, this invention, through virus inhibition research, has for the first time discovered that the active monomers of Terminalia chebula, chebulic tannin and punicalin, both Omicron BA.1 and BA.2 virus strains, have significant inhibitory effects, with extremely low half-maximal effective concentrations (IC50). Therefore, Terminalia chebula or its active monomers chebulic tannin and punicalin, or Terminalia chebula extracts containing at least one of these two active monomers, can be used to formulate products that inhibit the novel coronavirus and products that combat Omicron virus. Attached Figure Description

[0029] Figure 1 IC50 of Terminalia chebula tannic acid in Example 1 of this invention 50 curve;

[0030] Figure 2 IC50 of pungent glycoside in Example 1 of this invention 50 curve;

[0031] Figure 3 This is from Example 1 of the present invention, which evaluates the effect of Terminalia chebula tannic acid on SARS-CoV-2 M based on plasmon surface resonance. pro The result of intermolecular interactions;

[0032] Figure 4 This is from Example 1 of the present invention, which evaluates the effect of punicalin on SARS-CoV-2 M based on plasmon surface resonance. pro The result of intermolecular interactions;

[0033] Figure 5 This invention demonstrates the inhibitory effects of Terminalia chebula tannic acid and punicalin on Omeprone BA.1 and Omeprone BA.2 virus strains in Example 2 of this invention. Detailed Implementation

[0034] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below with reference to specific embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.

[0035] The Omegavirus strain is more infectious than the novel coronavirus and replicates faster in the bronchi. Currently used drugs for COVID-19 are ineffective or even useless against the Omegavirus strain. Furthermore, drugs obtained through virtual screening of virtual targets do not always inhibit replication or kill the virus when applied to COVID-19, and are also not necessarily effective against variant strains of the virus.

[0036] To address this issue, the inventors conducted drug screening and in vitro pharmacodynamic verification using the novel coronavirus and Omeprone virus strains in a biosafety level 3 (P3) laboratory.

[0037] Traditional Chinese medicine (TCM) plays an important role in treating COVID-19, but there are thousands of types of TCM, and not every type can be used to treat COVID-19. Furthermore, not all components of TCM effective against COVID-19 have inhibitory or killing effects on the virus. Coronavirus main protease (M...) pro (M) is a proteolytic enzyme that hydrolyzes and processes replicase precursor polymerases, releasing the polymerases and helicases required for viral RNA replication, participating in key steps of the viral replication process. Based on extensive research of traditional Chinese medicine, the inventors conducted in-depth research on the astringent herb Terminalia chebula, based on the M... pro Structural analysis of SARS-CoV-2 M pro The recombinant plasmid was transformed into E. coli and purified to obtain SARS-CoV-2 M. pro Using in vitro enzymatic activity assays, the enzyme inhibitory activities of dozens of small molecules contained in Terminalia chebula were investigated. It was found that chebulic tannic acid and punicin inhibited the activity of enzymes against SARS-CoV-2 M. pro It has a strong binding affinity and a significant inhibitory effect on it.

[0038] Furthermore, by infecting African green monkey kidney cells Vero E6 (ATCC, CRL-1586) with Omicron BA.1 and BA.2 virus strains, the inventors discovered for the first time that chebulic tannin and punicin from the astringent herb Terminalia chebula have a significant inhibitory effect on the Omicron virus strain, exhibiting extremely low half-maximal effective concentration (EC50). 50 ).

[0039] Based on the research results, this invention provides the application of Terminalia chebula and its active monomers in the preparation of products that inhibit the novel coronavirus and are effective against Omeprone virus.

[0040] Due to the effects of Terminalia chebulic acid and punicin on SARS-CoV-2 M proIt exhibits significant inhibitory effects and strong binding affinity, with an extremely low half-maximal effective concentration (HMC) for Omega virus strain. Therefore, it can achieve ideal therapeutic effects at relatively low dosages and is expected to become an active ingredient with good application prospects for products inhibiting the novel coronavirus and Omega virus.

[0041] The present invention will be described below through specific embodiments.

[0042] The small molecule standards of traditional Chinese medicine used in the following examples were all purchased from Shanghai Yuanye Biotechnology Co., Ltd., and their HPLC purity was greater than 98%. SARS-CoV-2 M pro The recombinant plasmid was provided by Academician Rao Zihe's research group at the Institute of Immunochemistry, ShanghaiTech University.

[0043] Example 1

[0044] This embodiment provides the effects of chebulic tannic acid and punicin on SARS-CoV-2 M. pro The inhibitory effect.

[0045] 1. SARS-CoV-2 M pro Expression and purification

[0046] SARS-CoV-2 M pro The recombinant plasmid was transformed into competent E. coli BL21(DE3) cells, and positive clones were screened using LB plates (containing 100 mg / L ampicillin); SARS-CoV-2 M pro The nucleotide sequence of the recombinant plasmid (as shown in SEQ ID NO.1) is as follows:

[0047] SGFRKMAFPSGKVEGCMVQVTCGTTTLNGLWLDDVVYCPRHVICTSEDMLNPNYEDLLIRKSNHNFLVQAGNVQLRVIGHSMQNCVLKLKVDTANPKTPKYKFVRIQPGQTFSVLACYNGSPSGVYQCAMRPNFTIKGSFLNGSCGSVGFNID YDCVSFCYMHHMELPTGVHAGTDLEGNFYGPFVDRQTAQAAGTDTTITVNVLAWLYAAVINGDRWFLNRFTTTLNDFNLVAMKYNYEPLTQDHVDILGPLSAQTGIAVLDMCASLKELLQNGMNGRTILGSALLEDEFTPFDVVRQCSGVTFQ.

[0048] Positive clones (single clones grown on LB plates containing ampicillin) were picked from LB plates, cultured overnight, and then transferred to 1L of LB medium (containing 100mg / L ampicillin). When the OD600 reached 0.6–0.8, about 1mM of IPTG was added, and the plates were cultured at 16°C for about 16 hours.

[0049] Collect the bacterial culture by centrifuging at 4000 rpm for 15-20 min, then break the bacteria with an autoclave, and collect the supernatant after centrifuging the bacterial culture at 13000 rpm for 40 min.

[0050] The supernatant was added to a nickel affinity chromatography column pre-equilibrated with Tris-HCl. The column was eluted with Tris-HCl (containing 20 mM imidazole) for 5-10 column volumes to remove contaminating proteins, followed by elution with 300 mM imidazole. Finally, human rhinovirus 3C protease was added, and the mixture was digested at 4°C for 12-20 hours. The protein was then collected and concentrated to obtain SARS-CoV-2 M. pro .

[0051] 2. Terminalia chebulic acid and punicein have effects on SARS-CoV-2 M pro Inhibitory effect

[0052] SARS-CoV-2 M pro The activity assay used the fluorescent substrate MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 (purity ≥98%), which has an MCA fluorescent group attached to its N-terminus (absorption wavelength 320 nm, emission wavelength 405 nm).

[0053] (1) Single-point inhibition rate screening:

[0054] Dozens of small molecules of traditional Chinese medicine contained in Terminalia chebula were analyzed for SARS-CoV-2 M. pro In vitro inhibitory activity was investigated. The inhibitory activity was studied in vitro using SARS-CoV-2 M... pro Different buffer solutions (50 mM Tris-HCl (pH 7.3), 1 mM EDTA (with or without DTT) were used to add SARS-CoV-2 M proAdd the above-mentioned small molecule standards of traditional Chinese medicine to the solution (final concentration 0.2 μM) to achieve a final concentration of 40 μM. Incubate at room temperature for 1 h, then immediately add the fluorescently labeled substrate (MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2, final concentration 20 μM). The excitation and emission wavelengths are 320 nm and 405 nm, respectively. Maintain the temperature at 298 K and record fluorescence readings every 10 seconds. Use the control curve as the assay curve when only protein and substrate are added, without any inhibitors. The lower the curve, the stronger the inhibitory effect. When the inhibition rate of the main protease is greater than 90%, further determine the IC50 of the compound. 50 .

[0055] Experiments have shown that chebulic tannic acid and punicalin are effective against SARS-CoV-2 M. pro The inhibition rate is greater than 90%.

[0056] (2)IC 50 Measurement

[0057] Terminalia chebulic acid and punicalin were respectively diluted in 12 serially diluted concentrations with 0.2 μM SARS-CoV-2 M. pro The mixture was prepared by mixing 20 mM Tris-HCl at pH 8.0 and 150 mM NaCl, incubating at room temperature for 1 h, then adding 20 μM of the substrate peptide, reacting at room temperature, and immediately detecting the results using a microplate reader. All experimental data were analyzed using GraphPadPrism, and IC50 was obtained by plotting the data. 50 .like Figure 1 As shown, chebulic tannic acid, within a concentration range of 0.039 μM to 160 μM, has an effect on SARS-CoV-2 M. pro It has a significant inhibitory effect. For example... Figure 2 As shown, pungentin, within the concentration range of 0.195 μM to 30 μM, has an effect on SARS-CoV-2 M. pro It has a significant inhibitory effect.

[0058] 3. Terminalia chebulic acid and punicalin are related to SARS-CoV-2 M pro Molecular interaction research

[0059] Evaluation of Terminalia chebula tannic acid and punicalin in relation to SARS-CoV-2 M based on surface plasmon resonance (SPR) pro The interaction between them.

[0060] The experiment was conducted using a Biacore T200 micrometer, and SARS-CoV-2 M... proThe transcribed sensor chip CM5 was coupled via an amino coupling reaction. Terminalia chebulic acid and punicalin were serially diluted with working solution (PBS-P, 5% DMSO) from 0.12 to 31.25 mmol / L and injected into the channel at a flow rate of 10 μL / min. The coupling time was set to 120 s, and the dissociation time to 300 s. Data were analyzed using Biacore T200 evaluation software, affinity curves were fitted, and the equilibrium dissociation constant (K0) was obtained. D ).

[0061] The results are as follows Figure 2 and Figure 3 As shown, Terminalia chebula tannic acid and SARS-CoV-2 M pro K D The value was 0.289 μM, indicating that pungent glycosides were similar to SARS-CoV-2 M. pro K D The value was 0.235 μM, which is consistent with SARS-CoV-2 M. pro It has a strong affinity for binding.

[0062] Example 2

[0063] This embodiment provides in vitro pharmacodynamic experiments and results of chebulic tannic acid and punicin against the novel coronavirus.

[0064] The experiment used the African green monkey kidney cell line Vero E6 (ATCC, CRL-1586) and the Omicron BA.1 and BA.2 virus strains. The cell infection dose was MOI = 0.01, i.e., 102 4 One hundred viruses infect one cell.

[0065] Before drug administration, 100 μL of Vero E6 cells were added to each well of a 96-well plate to make the cell count 2 × 10⁶ cells per well. 4 Each, incubated for 24 hours.

[0066] The compound was serially diluted 3-fold at the highest concentration of 100 μM, resulting in 8 concentration gradients. Each concentration was performed in 8 replicates (8 times in total). Omicron BA.1 or BA.2 was added to each well to infect cells. After 48 h of infection, the cells were read using a Celigo Image Cytometer. The half-maximal effective concentration (EC50) was calculated based on the cytopathic effect. 50 The result is as follows: Figure 5 As shown, Terminalia chebula tannins have an effect on the EC50 of Omicron BA.1. 50 The concentration was 0.81 μM for EC50 of Omicron BA.2.50 The EC50 of punicalin against Omicron BA.1 was 1.19 μM. 50 The concentration was 4.37 μM, for EC50 of Omicron BA.2. 50 It is 3.65 μM.

[0067] The results show that chebulic tannic acid and punicin have a very significant inhibitory effect on Omicron BA.1 and BA.2 virus strains, and can be used to prepare products against Omicron virus.

[0068] Example 3

[0069] This embodiment provides a face mask, the preparation method of which is as follows:

[0070] Non-woven fabric is soaked in a Terminalia chebula extract containing Terminalia chebula tannic acid or punicin, and then dried. The resulting dried non-woven fabric is used as the interlayer of a mask and the mask is made according to conventional mask manufacturing methods.

[0071] Example 4

[0072] This embodiment provides a face mask, the preparation method of which is as follows:

[0073] Non-woven fabric is soaked in a Terminalia chebula extract containing Terminalia chebula tannic acid and punicin, and then dried. The resulting dried non-woven fabric is used as the interlayer of a mask and the mask is made according to conventional mask manufacturing methods.

[0074] Example 5

[0075] This embodiment provides a mouthwash containing 160 μM chebulic tannic acid, 50 mL / L glycerin, 3 wt% sorbitol, 0.3 wt% sodium ascorbate, and the remainder being water.

[0076] Example 6

[0077] This embodiment provides a mouthwash containing 30 μM punicalin, 50 mL / L glycerin, 3 wt% sorbitol, 0.3 wt% sodium ascorbate, and the remainder being water.

[0078] Example 7

[0079] This embodiment provides a mouthwash containing 80 μM chebulic tannic acid, 15 μM punicalin, 50 mL / L glycerin, 3 wt% sorbitol, 0.3 wt% sodium ascorbate, and the remainder being water.

[0080] Example 8

[0081] This embodiment provides a hand sanitizer with the following components: 120 μM Terminalia chebulic acid, 6 wt% glycerin, 7 wt% disodium cocoamphodiacetate, 2 wt% PEG-10 oleate, 0.02 wt% phenoxyethanol, and the balance being water.

[0082] Example 9

[0083] This embodiment provides a hand sanitizer containing 20 μM punicin, 6 wt% glycerin, 7 wt% disodium cocoamphodiacetate, 2 wt% PEG-10 oleate, 0.02 wt% phenoxyethanol, and the balance being water.

[0084] Example 10

[0085] This embodiment provides a hand sanitizer containing 60 μM chebulic tannic acid, 10 μM punicalin, 6 wt% glycerin, 7 wt% disodium cocoamphodiacetate, 2 wt% PEG-10 oleate, 0.02 wt% phenoxyethanol, and the balance being water.

[0086] Example 11

[0087] This embodiment provides a no-rinse spray containing 120 μM Terminalia chebulic acid, 3 wt% glycerin, 2 wt% PEG-7 olive oil ester, 0.015 wt% phenoxyethanol, and the balance being water.

[0088] Example 12

[0089] This embodiment provides a no-rinse spray containing 20 μM pungent glycoside, 3 wt% glycerin, 2 wt% PEG-7 oleic acid ester, 0.015 wt% phenoxyethanol, and the balance being water.

[0090] Example 13

[0091] This embodiment provides a no-rinse spray containing 60 μM chebulic tannic acid, 10 μM punicalin, 3 wt% glycerin, 2 wt% PEG-7 olive oil ester, 0.015 wt% phenoxyethanol, and the balance being water.

[0092] Example 14

[0093] This embodiment provides a no-rinse gel containing 110 μM chebulic tannic acid, 8 wt% glycerin, 0.3 wt% carbomer 980, 0.6 wt% citric acid, 0.5 wt% sodium metabisulfite, and the balance being water.

[0094] Example 15

[0095] This embodiment provides a no-rinse gel containing 20 μM pungent glycoside, 8 wt% glycerin, 0.3 wt% carbomer 980, 0.6 wt% citric acid, 0.5 wt% sodium metabisulfite, and the balance being water.

[0096] Example 16

[0097] This embodiment provides a no-rinse gel containing 55 μM chebulic tannic acid, 10 μM punicalin, 8 wt% glycerin, 0.3 wt% carbomer 980, 0.6 wt% citric acid, 0.5 wt% sodium metabisulfite, and the balance being water.

[0098] Example 17

[0099] This embodiment provides a disinfectant solution whose main component is 100 μM Terminalia chebulic tannic acid, and the remaining component is water.

[0100] Example 18

[0101] This embodiment provides a disinfectant containing 16 μM pungent glycoside and water as the remaining component.

[0102] Example 19

[0103] This embodiment provides a disinfectant solution whose components are 50 μM chebulic tannic acid, 8 μM pungent glycoside, and the remainder being water.

[0104] Example 20

[0105] This embodiment provides a disinfectant wipe, which is prepared as a solution consisting of 100μM chebulic tannic acid, 2wt% glycerin, 0.015wt% phenoxyethanol, and the balance being water. The wipe is obtained by soaking non-woven fabric in the solution and then packaging it.

[0106] Example 21

[0107] This embodiment provides a disinfectant wipe, which is prepared as a solution containing 16μM pungent glycoside, 2wt% glycerin, 0.015wt% phenoxyethanol, and the balance being water. The wipe is obtained by soaking non-woven fabric in the solution and then packaging it.

[0108] Example 22

[0109] This embodiment provides a disinfectant wipe, which is prepared as a solution containing 50 μM chebulic tannic acid, 8 μM pungent glycoside, 2 wt% glycerin, 0.015 wt% phenoxyethanol, and the balance being water. The wipe is obtained by soaking non-woven fabric in the solution and then packaging it.

[0110] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions or improvements made within the spirit and principles of the present invention should be included within the protection scope of the present invention.

Claims

1. The application of Terminalia chebula in the preparation of products against Omeprazole virus, characterized in that, The active ingredients of the product include Terminalia chebula and / or Terminalia chebula extract, wherein the Terminalia chebula extract includes at least one of Terminalia chebulic tannic acid and punicin, and the Omeprone virus strain includes at least one of BA.1 and BA.2 virus strains.

2. The application according to claim 1, wherein the product includes pharmaceuticals and daily chemical products.

3. The application according to claim 2, characterized in that, The daily chemical products include masks, mouthwash, hand sanitizer, hand rinse spray, hand sanitizer gel, disinfectant, and disinfectant wipes.

4. Application of Terminalia chebula tannic acid in the preparation of products against Omeprone virus.

5. Application of pungent glycoside in the preparation of products against Omeprazole virus.

Images